“Dapagliflozin and Sitagliptin Combination Therapy: An Overview of Clinical Utility in Type 2 Diabetes Mellitus With Multiple Cardiovascular Risk Factors”. 2023. Cardiology and Cardiovascular Medicine 7 (2): 141-44. https://fortunejournals.org/ojs/index.php/ccm/article/view/16403.